Currently, there are 188.84M common shares owned by the public and among those 187.59M shares have been available to trade.
The company’s stock has a 5-day price change of -4.72% and -39.21% over the past three months. LCTX shares are trading -49.83% year to date (YTD), with the 12-month market performance down to -44.96% lower. It has a 12-month low price of $0.50 and touched a high of $1.61 over the same period. LCTX has an average intraday trading volume of 1.25 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -27.75%, -33.78%, and -45.04% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Lineage Cell Therapeutics Inc (AMEX: LCTX) shares accounts for 50.52% of the company’s 188.84M shares outstanding.
It has a market capitalization of $103.26M and a beta (3y monthly) value of 1.16. The earnings-per-share (ttm) stands at -$0.11. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.98% over the week and 9.94% over the month.
Earnings per share for the fiscal year are expected to increase by 6.67%, and -7.14% over the next financial year.
Looking at the support for the LCTX, a number of firms have released research notes about the stock. Craig Hallum stated their Buy rating for the stock in a research note on August 20, 2024, with the firm’s price target at $4. Robert W. Baird coverage for the Lineage Cell Therapeutics Inc (LCTX) stock in a research note released on November 02, 2022 offered a Outperform rating with a price target of $5. B. Riley Securities was of a view on June 14, 2022 that the stock is Buy, while Noble Capital Markets gave the stock Outperform rating on August 19, 2021, issuing a price target of $8. Cantor Fitzgerald on their part issued Overweight rating on March 31, 2021.
